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1. Introduction
Hepatocellular carcinoma (HCC is the fifth most common cause of mortality worldwide and
the third cancer related cause and is responsible for about 1 million deaths yearly [1]. The age-
adjusted worldwide incidence is 5.5-14.9 per 100.000 population. In some areas of the world,
such as sub-Saharan Africa and Southeast Asia, HCC represents the first cause of cancer death
with an incidence of 52 per 100.000. Furthermore, in Europe and USA, HCC incidence has
progressively raised in the past decade representing a burden problem.
HCC is one of the few cancers for which a number of risk factors are known in great detail [2,
3]. HCC is almost always (80%) associated with cirrhosis, at least in developed countries, and
chronic hepatitis C and B infection, alcoholic cirrhosis and haemocromatosis are some of the
established risk factors [4]. The metabolic syndrome related to hypertension, central obesity,
diabetes and obesity has been identified as a new risk factor. As a result, screening programs
have developed, with the use of ultrasound and α-fetoprotein (AFP), with a hope to increase
the chances of diagnosing small HCC and unltimately increase the rate of curability.
Definitive diagnosis relies on the demonstration of a typical vascular pattern per liver imaging
techniques (triple-phase CT-scan or MRI) of tumors larger than 2 cm with arterial hypervascu‐
larity and venous wash- out. Nodules, smaller than 2 cm, should be rechecked every six months
or, if highly suspect, subjected to needle biopsy. It’s likely that the study of tumor-specific tissue
markers with prognostic value could introduce a systematic use of needle biopsy.
Over the past 20 years, surgical treatment of hepatocellular carcinoma has seen an immense
boost and improvement, with good survival outcomes and reduced morbidity and mortality.
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Liver resection (LR) and orthotopic liver transplantation (OLT) and ablative therapies are now
considered the only potentially curative treatments for this cancer. LR has achieved improve‐
ment in survival within the past decade as a result of advances in diagnosis, surgical man‐
agement of HCC and perioperative care. However, the long-term prognosis remains poor, and
the 5-year overall survival rate ranges between 33% and 44%, with a 5-year cumulative
recurrence rate of 80% to 100%.
OLT could be viewed as the optimal treatment for HCC that is accompanied by advanced
cirrhosis because of the widest possible resection margins for tumour and for a definitive cure
of cirrhosis and its related complications. OLT for HCC performed within well-defined
oncologic criteria (Milan criteria “reference”) has shown long-term results comparable with
those of transplantation for non-HCC patients. However, the critical shortage of available
donated organs, together with the increasing number of patients awaiting transplantation,
makes this therapeutic option available to only a small percentage of patients. Owing to the
limited organ supply, many liver transplant centers usually make a selection to resect patients
with compensated liver cirrhosis, defined as Child–Pugh A chronic liver disease and resectable
tumor and to reserve transplantation for those with impaired liver function (Child-Pugh class
B-C) and small oligonodular HCC considered within the currently accepted criteria for
transplantation.
Radiofrequency and microwave ablation are relatively new percutaneous techniques in
clinical use for HCC, that can produce tumour necrosis. Complete response rates are high in
large series if tumour is less that 3 cm in diameter.
This chapter will consider the main surgical techniques for the treatment of HCC in the light
of the major guidelines currently available and of personal experience.
Also, we will review HCC prognostic factors, and the particular situation of “large” HCC and
the strategy for liver tumours located at the hepato-caval confluence.
2. Surgical approach to HCC
Until two decades ago, prognosis of HCC was considered inevitably poor. Survival values of
54%, 40% and 28% at 1, 3 and 5 years in a group of patients with unresectable HCC were
reported [5]. Since then, the therapeutic approach and the prognosis have been significantly
modified [6], overall survival rates at 5 yearsreached values of 35-70% for liver resection [7,
8] and 40-75% for liver transplantation, depending on the stratification system of patients [9,
10]. This mainly related to better allocation of patients to current available treatments (OLT,
LR, local therapies), enhancement of post-operative care, and treating patients at centers with
a high-volume of hepatic surgeries. With regard to LR there has been an improved balance
between extent of resection and parenchymal volume spared, a systematic use of intraopera‐
tive ultrasound examination (IOUS), and meticulous care to minimize blood loss by mean of
intermittent clamping of the portal triad [11], selective clamping, and use of innovative
hemostatic tools for dissection as ultrasound dissectors, harmonic scalpel, and argon-beamers.
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Side by side, some new techniques, such as portal vein embolization to induce hypertrophy
of the remnant liver, and intraoperative radiofrequency (RFA) or microwave (MWA) ablation
have allowed it to expand and optimize the surgical offer. HCC occurs in over 80% of cases of
cirrhosis. Furthermore, both tumor and cirrhosis contribute to the risk of mortality, and
cirrhosis represents a limit for hepatic resection due to the risk of liver failure.
For HCC arising in the setting of healthy liver, it is undisputed that resection represents the
first line of treatment; parenchymal resections extended up to 60% of the organ fall within an
acceptable risk of post-operative liver failure and mortality.
Conversely, for HCC accompanied by cirrhosis, surgical outcome and prognosis are depend‐
ent on the degree of cirrhosis, independent of the tumor stage. In general, considering only the
size of the tumor, three categories of HCC could be defined: (<3 cm), -(3-5 cm), a (5-10 cm) and
(> 10 cm). The outcome after resection is good in the setting of smaller tumorsand the results
after transplantation are optimal for single tumor<5cm or up to 3 tumors, <3cm each (Milan
criteria). Furthermore tumor ablation by percutaneous alcohol treatment or RF ablation is
optimal for tumors in the first category, and in select cases in the second, not applicable for
tumors >5 cm. These results depend on the fact that, with an increase in the tumor size there
increases the likelihood of vascular infiltration, poor tumor grading 3-4, satellites nodules, and/
or multinodularity which represent (in particular the first two) a strong negative prognostic
factors. If it is true that the best results in terms of survival are obtained for single lesion, there
is now agreement that multiple nodules, up to 3, and no larger than 3cm can be addressed to
transplantation with results similar to those of single tumor < 3 cm. Percutaneous ablative
therapies or multiple resections, or resections supplemented by intraoperative ablation also
offer discrete survival results in selected cases. The presence of a peritumoral capsule (in the
so-called expansive capsulated HCC) represents another favorable prognostic element, while
vascular infiltration, both microscopic and macroscopic, even more drastically reduces
survival expectancy, because it determines an additional risk of early recurrence. Improved
knowledge of the weight of these prognostic factors has led to the development of pathological
classification systems very useful for evaluating the prognosis in non-surgical cases. AJCC /
UICC pathological classification [12] devotes particular concern to the presence of macroscopic
vascular infiltration or infiltration of large venous branches seen on imaging scans, but not to
the size of the lesion, which is useful for prognostic purposes. The classification of the American
Liver Tumor Study Group [13] also used by the United Network of Organ Sharing (United
Network for Organ Sharing - UNOS 2012) [14] takes into account the size and nodularity of
HCC tumors and is used to evaluate patients before resection or transplantation.
Finally, another HCC tumor parameter, which is critical to treatment decisionsis of the tumor
location within the liver and its relationship with vascular structures. This technical aspect
isespecially relevant to small tumors that are centrally located, or close to the main portal
branches or to the hepato caval confluence, which should be considered for percutaneous
therapy or transplantation, given the difficulty of extensive resection in this setting. In addition,
other aspects related to the underlying liver disease must be addressed, such as the presence
of portal hypertension (with pressures > 10mmHg), or platelets <100,000 that are associated
with poor survival outcome following surgery, and increased bilirubin levels.
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3. Liver resection and assessment of liver function
Problems to be faced in order to formulate a correct indication to resection are linked to 1)
general conditions of the patient, in particular the presence of co-morbidities, 2) stage of the
tumor, and 3) presence of advanced cirrhosis and hepatic function status which represent a
limiting condition to hepatic resection and a real risk of postoperative liver failure, this being
the major cause of mortality.
Liver function in cirrhotic liver is evaluated using different models, none of which is more
useful than others in predicting of residual liver function after resection. Child-Turcotte-Pugh
(CTP) [15] is the functional classification still widely used in most Western Centers: patients
who fall within class A can be submitted to resection, even extended, with a low risk of liver
failure, patients in class B are better candidates for non-surgical procedures (such as RFA, or
transarterial chemoembolization), while those belonging to class C can only aspire to a
transplant (Table 1) if within Milan criteria and good surgical candidates. However, the
accuracy of CTP in predicting survival and treatment outcome has been questioned. Further‐
more, this classification based only on few functional aspect of the liver is of limited utility in
a decisional algorithm that must take into account also pathological aspects of the tumor.
For this reason, attempts have been made to integrate functional aspects of cirrhotic liver and
tumor features. An example of these attempts is the Okuda classification (Table 2) [16] which
combines tumor burden expressed as a percentage value of liver measure (< 50% or > 50%),
with other functional and clinical variables: bilirubin and albumin levels, and the presence of
ascites. Okuda’s classification is certainly useful for predicting the risk of post-operative
complications but not the results of long-term survival. In untreated patients with HCC on
cirrhosis, this classification has proved to be highly predictive of survival.
Point Bilirubin
( mg/dL)
Prothrombin time Albumin
(g/dL)
Ascites Encefphalopathy
(grade)
1 < 2 "/> 70% "/> 3.5 None None
2 2-3 40-70% 2.8-3.5 Slight 1-2
3 "/>3 < 40 % < 2.8 Moderate 3-4
Stage Score
A 5-6
B 7-9
C ≥ 10
Table 1. Child-Pugh-Turcotte Score
In many Centers, especially Asians, CPT score is supplemented with the indiocyanin green
clearance test (ICG) [17, 18]. Indocyanine Green dye is exclusively cleared from the blood by
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the liver. A value of ICG at 15 minutes ≤ 14% is considered as predictive of a good functional
reserve that allows resection of more than two segments according to Couinaud classification,
both in patients in class A as well as for those in CPT class B [17, 19, 20]. Compared to only
CPT score, ICG15r offers a prediction of the extent of liver resection [11] (Figure 1).
Figure 1. Possible extent of liver resection based on ICGr15 test.
It should be noted that these methods of evaluating liver function do not directly consider the
presence and degree of portal hypertension, which instead is withheld as an high risk factor
of post-operative morbidity in most Western Centers. Guidelines of the ’European Association
of the Study of the Liver (EASL 2005) in fact, strongly recommend to preclude resection to
Criterion Cut-off
+ -
Tumor size (*) "/> 50% < 50%
Ascites Clinically detectable Absence
Albumin < 3g/dL "/> 3 g/dL
Bilirubin "/> 3 mg/dL < 3mg/dL
Stage I No positives
Stage II One or two positives
Stage III Three or four positives
Table 2. Okuda staging system. (*) Largest cross-sectional area of tumor to largest cross-sectional area of liver
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patients with portal hypertension (PHT) with hepatic venous portal gradient (HVPG) >
10mmHg [5, 21, 22]. According to EASL guidelines, direct measurement of veno-portal
gradient is more appropriate than an indirect assessment for the presence of esophageal
varices, splenomegaly, and thrombocytopenia [23]. Recently hepatic elastography, which is a
measure of the parenchymal "stiffness" would seem to linearly correlate with the values of
HVPG, and may be considered as a simple alternative to the direct measurement [24, 25].
Notably, in late 1990s, another classification was proposed, named Barcelona Clinic Liver
Cancer (BCLC) staging; which takes into account both variables linked to the tumor, and
patient’s conditions (CTP), to be also used as a treatment alloction system (Table 3) [5].
BCLC stratifies patients depending on the size and features of the tumor in four categories or
stages: early stage (quite broad: single tumor up to 5 cm in diameter or up to three HCC with
a diameter of <3 cm), intermediate stage, advanced and terminal stages. For each category,
after considering the performance status, values of bilirubin and presence or absence of portal
hypertension, each patient is assigned to a specific treatment modality (resection, transplan‐
tation, percutaneous treatment (PEI, RF, MW) which should offer the expectation of survival
and treatment outcome.
Stadio Tumor features Clinical features
Stage A (EC early)
A1 PST 0 Single tumor Portal hypertension absent, normal
bilirubin levels
A2 PST 0 Single tumor Portal hypertension present, normal
bilirubin levels
A3 PST 0 Single tumor Portal hypertension present,
abnormal bilirubin levels
A4 PST 0 3 nodules less than 3 cm Child Pugh A-B
B (EC intermediate) PST 0 Multinodular Child Pugh A-B
C (EC advanced ) PST 1-2 Vascular infiltration and extrahepatic
extension
Child Pugh A-B
D (EC end stage) PST 3-4 Any Child Pugh C
Table 3. BCLC staging system (Barcelona Clinic Liver Cancer). PST: performance Status Test.
Notably, the American Association for the Study of the Liver guidelines (AASLD) [26], adopted
BCLC HCC staging. The Asia-Pacific Association for the Study of the Liver (APASL) [27]
maintained a bolder position: it does not evaluate a "functional reserve", and even puts a limit
in the presence of portal hypertension, reflecting different development experience in Eastern
Centers. The gap between the two guidelines is expanded even more if it considers the tumor
burden, in fact AASLD guidelines recommend liver resection only in the presence of a single
HCC, while APASL guidelines allows resection if HCC is confined to the liver, if the portal
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trunk is patent and the resection technically feasible, verbatim “Liver resection is a first-line
curative treatment of solitary or multi-focal HCC confined to the liver, anatomically resectable,
and with satisfactory liver function”. This recommendation is obviously very different from
that of the AASLD, verbatim “Patients who have a single lesion can be offered surgical
resection if they are non-cirrhotic or have cirrhosis but still have preserved liver function,
normal bilirubin and hepatic vein pressure < 10 mm Hg”.
Thus, HCC staging and treatment allocation reflect a certain methodological variability [28]
determined by ethical and social influences, and different practical needs of the different health
care systems worldwide, which ultimately produce center-specific selection criteria.
4. Indication to liver resection
Resection for HCC is placed on the basis of two preliminary “technical” considerations:
1. Amount of liver function reserve and value of residual liver volume (RLV).
2. Anatomical location and extent of the tumor.
Single HCC below 5 cm, or multifocal HCC (not more than three tumors) without vascular
invasion and with limited dimensions (<3 cm each), offer very good survival results that reach
50% at 5 years [29–31], and up to 70% at 5 years in a category of patients with normal bilirubin
values and absence of portal hypertension [5]. In view of these results, there is a rather frequent
disease relapse, estimated in terms of 50% at 3 years, 70% at 5 years and > 80% at 10 years [29–
32]. Since these hopeful survival results (in particular for single HCC < 3 cm) were consistent
with those of percutaneous ablation therapies, and slightly lower than those of transplantation,
the choice of the procedure essentially depends on the experiences of the treating center [26].
The best results in terms of survival and low disease recurrence are offered by transplant
specially in cases with established cirrhosis, even if, on a basis of "intention-to-treat" compar‐
ison the difference tends to be closer [33]. However, the option of liver transplantation is clearly
limited by the shortage of organs supply. In 2010, based on the Organ Procurement and
estimated Transplantation Network (OPTN), average waiting list time ranged from 140 days
for American Indians up to 651 days for Hispanics [34]. Depending on the wait time period
and the selection criteria used, the dropout rate for patients with HCC awaiting LT ranged
between 12% and 38% [10, 35–37], and was essentially linked to tumor progression. Therefore,
for early stage HCC transplantation should be reserved for those patients with poor liver
function (eg CPT class C), and/or with evidence of portal hypertension. Since the report from
Mazzaferro on the results of liver transplantation in a very well defined category of HCC, with
actuarial 4-year overall survival of 85% and disease-free survival of 92%, subsequently
confirmed by others, the "Milan criteria" [9] has marked an important turning point towards
a more homogeneous transplant indication. Subsequently, other centers [38] have attempted
to expand these criteria with fairly consistent results. However, the favorable results of
transplantation for HCC within the Milan criteria must be considered very carefully, because
it may be influenced from a selection bias. In fact, stratifying patients for factors other than
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size (for example for the presence of vascular invasion), survival curves between OLT and LR
showed a similar trend [39]. Many high volume centers for HCC treatment reported that
patients eligible for OLT (within the Milan criteria), but subjected to liver resection showed 5-
year actuarial survival rate of about 60-70%, [6, 8, 40–45], in particular in a subgroup of patients
without vascular invasion [39, 42–48].
Taking into account these observations, it seems appropriate to offer hepatic resection to
patients with preserved liver functions who may be also eligible for transplantation, thanks to
the rapidity of care, the greater simplicity of resection compared to transplant, and the lower
rate of post-operative morbidity and mortality. Furthermore, it must be considered that
transplant exposes patients to the risk of toxicity and potentially fatal infections related to
immunosuppressive therapy, and predispose to the development of "de novo tumors".
In contrast, as previously mentioned, resection is associated with a higher recurrence rate
(50-70% at 5 years) given the persistent background defect of the underlying liver disease that
led to HCC development in the first place. Liver recurrence could be managed surgically (with
a re-resection) in selected cases, or through the use of percutaneous ablative therapies, or by
mean of “salvage transplant”. Recurrences rates are lower if tumors are within the Milan
criteria could benefit after orthotopic liver transplant as well as from split liver transplantation
(SLT), the latter, using of a portion of liver from a living or dead donor, allows a more rapid
access to liver transplantation. Two recent studies showed 5-year survival, morbidity and
recurrence rate after salvage transplant to be similar to OLT performed as first choice [41, 49].
Recurrence is influenced in part by HCC pathological criteroa such as satellites nodules,
vascular invasion, and poor histologic grading G3-G4. Translational research aimed at
identifying molecular characteristics of HCC predictive of high risk of recurrence will be
promising to avance this area of clinical challenge. Thus far, different chemoterapeutic agents
have been tested in the adjuvant setting to reduce the recurrence rate. However, the small
numbers of patients and the confounding variables did not lead to conclusive results.
The evidence gained to date for reducing the risk of recurrence has been linked to the surgical
technique details. In particular, during the exploratory time, intraoperative ultrasonography
should be systematically used for the correct evaluation of the position of the lesion, for the
exclusion of further lesions not identified at pre-operative imaging, and yet for a correct
evaluation of the vascular anatomy (Figure 2). It is estimated that 22 to 35% of the planned
resections could change as a result of the IOUS examination.
HCC tend to permeate portals pedicles causing "anatomical" metastases or tumor thrombi that
in turn are responsible of liver metastases (Figure 3). For this reason, many surgeons prefer to
perform anatomical segmental or sub-segmental resections rather than atypical or wedge
resections to ensure the inclusion of any microscopic satellite nodules, and tumor segmental
embolization [50]. The advantage of anatomic resections remains valid, even in cases of
multifocal lesions, as an alternative to extended resections such as hepatectomy or extended
hepatectomy, given the advantage of preserving the hepatic functional reserve [51]. In the case
of small centrally located HCC, and/or HCC proximal to major vascular pedicles, extensive
resections are required [52], but alternatively bi- or three-segmentectomy whenever feasible,
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offers the same oncologic advantage, and at the same time allows a second surgical approach
in case of relapse. Central resection (segments 5, 8, and 4), anterior-central resection (segments
4b and 5), posterior-central resection (segments 4° and 8), and lateral-superior bisegmentec‐
tomy (segments 7 and 8), and inferior-right bisegmentectomy (segments 6 and 5) represent an
economic alternatives to standard right hepatectomy.
The segmental nature of the liver has been reported by Bismuth [53] who described eight
segments, each of which is provided by an independent artero-portal and biliary pedicle.
Segments are easily identified by anatomical landmarks, or through the intraoperative
ultrasonography study of the portal branches distribution. A clear segmental demarcation
could be obtained through by ultrasound-guided direct puncture and flushing of the portal
branch with intravenous dye (methylene blue) tattooing the liver surface corresponding to the
perfused district; using small bilumen-catheters equipped with inflatable balloon, and the
Seldinger technique it is possible to simultaneously tattooing the liver surface (Figure 4) and
occluding the vascular lumen in order to stop blood flow to the segment, minimizing blood
loss, and theoretically reducing the risk of retrograde embolization from the tumor.
In general HCC ≤ 3cm can be treated with a segmentectomy, or with sub-segmentectomy, HCC
3-5 cm with segmentectomy eventually extended to contiguous subsegments, HCC> 5 cm may
require more extensive resections in order to provide a free margin from neoplasm of at least
1 cm (Figure 5).
Figure 2. Intraoperative ultrasound examination showing a small HCC of 2 cm (star mark) located in the eighth seg‐
ment and two minimal HCC (5 and 4 mm) (arrows) in the contiguous seventh segment. The planned resection of the
eight segment was changed to a bisegmentectomy of 7+8.
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With regard to the definition of the so-called "high-risk HCC", it is still controversial. The high-
risk HCC could be defined as:
1. “large”, those > 5 cm in diameter (Figure 6). Large HCC increases the risk of vascular
infiltration, worsening the prognosis. Even 10 years ago, 5-year survival after resection was
no more than 33%. Today survival rate for large HCC without vascular infiltration are
reported to be about 70% at 5 years [54] and 45% for so-called “giant HCC” (> 10cm) [55].
Figure 3. Modality of intrahepatic spreading of HCC. Tumor infiltrating sub-segmentary portal branches and deliver‐
ing tumor cells to the perifery (intra-segmental diffusion) (left). Tumor thrombus has invaded a portal pedicle and be‐
comes a source of dissemination at distance (intra- extra-segmental diffusion) (right).
Figure 4. Technic of tattooing liver segment. Staining a segment through a bilumen catheter introduced according to
Seldinger technique, after direct puncture under US guidance of a segmental portal pedicle (left). Blood flow occlu‐
sion inflating the balloon (optional) (center). Division of the parenchyma in segmental ischemic condition (left).
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2. “multifocal tumors”. Multifocality was considered for a long time as a contraindication
to surgical approach, since it is associated with a poor prognosis. The only feasible
treatment within the limits of small dimensions (3 nodules < 3cm each) is liver transplan‐
tation. However, many patients do not fall within the selection criteria and about 20% of
those selected experience progression and dropout from the waiting list. Thus, surgical
resection for patients with preserved liver functions may be the only curative option for
multifocal HCC. Global survivals from 29.9% to 58% are reported at present, depending
on the selection criteria [56, 57].
3. “macroscopic portal/hepatic vein involvement”. This condition indicates the worst
prognosis with a life expectancy of a few months in the absence of treatment.
In general, resectability for high-risk HCC is considered in absence of extrahepatic disease
(lymph node metastasis or extrahepatic hematogenous spread and contiguous organs
involvement), and in presence of preserved liver function. Due to the size, number, location
and vascular involvement of the tumor, major resections or multiple resections are required,
and are often associated with vascular reconstruction procedures. Limits to indication are the
percentage value of the estimated remnant liver, and feasibility of vascular reconstruction.
This configure a complex liver surgery that exposes at significatively higher morbidity/
mortality risk and different survival rates depending on specific Centers selection and
influenced by three main prognostic factors: grading, vascular infiltration, and size of the
tumor. However, if resection is technically feasible, long-term survival for these patients is
better than second-line therapy as trans-arterial chemo-embolization (TACE) [58, 59].
For multifocal and bilobar HCC although there are no randomized trials,there is anevidence
of cohort studies that rported successful resection in select cases [60, 61]. Resection can be
Figure 5. Tattooing of sub-segment of the fifth segment for a small HCC deeply located.
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combined with intraoperative ablation (RFA) expanding the rate of curability. Overall 5 years
survival between 39% and 58% for large, multifocal and vascular infiltrating HCC [57, 58, 62–
65] compared with the results of TACE overall survival of 24-63% at 2 years, and lowest rate
of survival at 5 years [66–68].
Recently, Delis [69] compared a group of 59 patients within the UCSF (abbreviation needs to
be defined..) liver transplant criteria (single tumor ≤6.5 cm, or three or fewer tumors of which
the largest ≤4.5 cm and the sum of the tumor diameter ≤8 cm) [38] and another group of 27
pateints who exceeded these criteria: all patients underwent hepatectomy or extended
hepatectomy with no mortality, but with higher rates of complications in the group that
exceeded the UCSF criteria. 1, 3 and 5 years disease-free survival were 66%, 37% and 34%,
respectively, in the first group and 56%, 29% and 26%, respectively, in the second group (p
<0.01), and the rate of recurrence was significantly higher in the second group, 74% vs 69% (p
<0.002). Vascular invasion was a strong predictive factor of intrahepatic and distant recur‐
rences. Therefore, major vascular invasion is considered a contraindication to surgery and
transplant in many surgical centers. Ikai [62] reports results of 66% and 43% 5-year survival
in HCC with and without vascular infiltration, and found better survival values for the cases
with tumor invasion of the portal branches of 2nd and 3rd order compared with invasion of
the portal trunk or main branches, or contralateral infiltration. The recurrence rate was high
(percentage??), but a considerable proportion of cases may be candidates for re-resection or
ablative treatments. In the presence of tumor invasion of the portal trunk, 5-year survival of
26.4% is reported (thrombosis with portal infiltration) and 28.5% (p =.33) (without portal
infiltration) [70]. According to some authors pre-treatment with TACE before resection can
increase the global values of 5-year survival up to 42% that is a value significantly higher than
7% observed in non resected patients [71]. Resection and reconstruction of the portal trunk or
Figure 6. A case of very large, or so-called “giant HCC” which measured > 30 cm in diameter and weighted 5 Kg, in‐
volving the entire right hepatic lobe. The tumor did not involve the portal trunk and the left lobe was hypertrophic.
Note the ischemic demarcation line (arrows) after selective right pedicle clamping.
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of the main portal branches represent a very small percentage of the total resections, but they
impose considerable technical difficulty because they require mobilization of the portal vein
to the pancreas, an accurate posterior skeletonization, and dissection of the contralateral portal
pedicle before the venotomy.
In the presence of hepatic veins involvement resection also extended to venous segments is
accompanied by global survival at 1 and 3 years of 88% and 50% respectively, with mortality
rates of 12% [72]. These are very selective indication procedure, which must be addressed at
highly skilled centers in the hepato-biliary-pancreatic surgery.
In conclusion, for high-risk HCC there are no guidelines supported by strong scientific evi‐
dence at the moment, but nevertheless, resection is offered more frequently in both Eastern and
Western Centers as well as in Academic Centers with a high volume of liver surgery [73–75].
5. Technical details
Major resection, defined as the resection of more than two segments (on liver with chronic
disease), does not involve particular risks of liver failure in patients with preserved functional
reserve (CTP class A), which can tolerate even more extensive resections, such as right or left
hepatectomy. However, except for cases of large HCC where the resected liver accounts for a
small proportion of functioning liver parenchyma, in other cases it is appropriate that a greater
hepatectomy is replaced by more limited resections, allowing to reduce the risk of postoper‐
ative liver failure, and maintaining the chance of a new intervention in case of recurrence.
As aforementioned, the choice of a segmental resection is standard because it reduces the
incidence of early complications, such as seromas, abscesses and in particular biliary leak. This
aspect should not be underestimated since postoperative infection could lead to increased risk
of liver failure.
An adequate knowledge of the vascular anatomy of the liver, the improvement of surgical
technique and post-operative care have allowed to extend resections for large tumors, select
cases of majorvascular involvement, saving the functioning segments, such as the salvage of
segment 6 to preserve the portal postero-inferior pedicle, or reconstructing hepatic vessels in
order to avoid vascular congestion of residual segments and/or sectors (Figure 7). Vascular
reconstruction can be of direct-type as hepato-caval, or with prosthetic interposition (generally
Gore-Tex), or venous segment interposition (portal or gonadal). This procedure can be
performed with direct vascular control, or with ex-vivo technique using veno-venous bypass.
Vascular reconstructions have the main purpose of avoiding the congestion of segments that
have no other way of direct outflow [76]. For these techniques a complete study of vascular
distribution preoperatively with CT-angiography and intraoperatively by mean of ultraso‐
nography is mandatory.
Intraoperative bleeding represents a further technical problem., In fact, blood loss affects both
the patient outcome in the short term, as well as the long-term survival and relapse. In the case
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of cirrhotic patients, bleeding is a cofactor of liver failure. Currently in high volume centers
for liver surgery, 50-70% of resected patients do not require blood transfusions.
To limit blood loss, Pringle maneuver or clamping the portal triad are the technique most
commonly used. Intermittent clamping of the hepatic hilum is preferred in cirrhotic patients
compared to continuous clamping aimed to limit ischemia/reperfusion damage. Typically,
clamping that determines a state of warm ischemia, is prolonged in cirrhotic up to 15 minutes.
In the case of prolonged resection times clamping can be repeated with periods of unclamping
(reperfusion) of 5 minutes (intermittent clamping). To limit the risk of ischemia/reperfusion
damage many surgeons employ the technique of pre-conditioning, which consists of 10
minutes clamping followed by 10 minutes reperfusion, which precedes the definitive clamp‐
ing. Pre-conditioning is believed to adapt liver parenchyma to warm ischemia thus reducing
the damage of ischemia/reperfusion. In fact, there is much evidence of this advantageous use
of the pre-conditioning in animal studies. However, evidence from few clinical studiesdoes
not conclude potential definite benefit in humans [77–79].
An elegant and effective alternative to the Pringle maneuver is vascular direct control by means
of ligation and division of the portal and arterial branches of the hepatic lobe to be resected if
a hepatectomy is planned, or its selective clamping in the course of segmental resections; thus
maintaining blood flow to the contralateral lobe. The selective exclusion of blood flow is
confirmed by a change in color (ischemic demarcation) on the surface of the liver lobe excluded.
Typically, if resections are performed with vascular control outset, the hepatic vein drainage
is identified and secured too, thus causing a total parenchymal ischemia. Under certain
Figure 7. Direct reconstruction of the middle hepatic vein (white arrows) after resection of HCC situated between seg‐
ment 8 and 4a. The yellow arrow indicates the upper segmental branch for segment 8.
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favorable circumstances of anatomical dissection (easy hilum), inflow vascular control can also
be obtained on second order branches (sectorial pedicles) determining a super-selective
ischemic control.
Clamping of the hepatic vessels is generally employed during major resections, while it is not
necessary if a small segmental resections, or wedge and laparoscopic resection are carried out
[80–82].
The interruption of the blood flow from the hepatic pedicle effectively reduces bleeding during
transection; however, bleeding could still results from the hepatic veins branches. To limit this
further source of bleeding, it is useful to conduct resection under low value of central venous
pressure (PVC) at less than 5 mmHg, and to place the patient in 20-25° Trendelemburg
decubitus. The value of CVP in fact is reflected both at the level of the hepatic veins as well as
at the sinusoidal compartment level, and blood volume lost during resection well correlates
with the value of CVP [83–86].
Intraoperative control of bleeding is further optimized by the use of different instruments of
parenchymal dissection, all aimed at containing bleeding from venular or sinusoidal origin.
Classical hepatic dissection is carried out through parenchymal crushing by means of the Kelly
or Klemmer clamps (crushing clamp technique): clamp pressure fractures the parenchyma
leaving uncovered blood vessels that, depending on the size, are secured by mean of coagu‐
lation device or sutures or clips. Alternatively one can employ tools that divide the parenchyma
in a gentler manner, through the ultrasonic dissector (ultrasonic dissection - CUSA-), bipolar
current instruments (LigaSure), or radio frequency device (Harmonic Scalpel), to list a few
examples. Although simple to use, the usefulness of these instruments is not clearin terms of
blood saving or shorter time of resection[87].
Another technical consideration related to expanding the possibility ofresection even in those
cases in which the total liver remnant volume is < 30% in healthy liver or < 35-40% in cirrhotic
liver is expected, which are the limits generally accepted to contain the risk of postoperative
liver failure [88, 89]. It is in fact possible to increase the volume of the hepatic remnant through
the mechanism of liver lobe induced hypertrophy occluding the contralateral portal branch,
the so-called portal vein embolization (PVE). This procedure is generally carried out under
local anesthesia, through the puncture of a portal branch under ultrasound guidance or by
fluoroscopy, which is then occluded by different embolizatin materials. This technique
determines a volumetric increase of the residual lobe of about 8 to 12% over the time of about
20-30 days. After PVE, the percentage of patients undergoing surgery ranges from 62 to 100%
according to recent studies [90, 91].
6. Indication to orthotopic liver transplantation
Since 1968 the "European Liver Transplant Registry” (ELTR) records all data of liver trans‐
plants in 145 centers across Europe. These data give an overview on what is the trend of
transplants in Europe during each period.
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Both the number of centers and the number of liver transplants gradually increased, but after
an exponential growth until the 80s, they reached a plateau that was maintained as shown by
recent data (ELRT) with about 5800 liver transplants performed per year across Europe.
Cirrhosis was the most common indication for liver transplantation (52%) rate, followed by
primary tumors of the liver (14%, HCC 12.1%).
Indication for liver transplantation have significantly changed over time. Subsequently, the
rate of liver transplantation for increased to 20% in late 1990s. Between 2000-2010, two groups
of indications have increased: primary tumors of the liver (16%), especially HCC, and cirrhosis
(53%), especially alcohol related (20%).
Transplantation for HCC has thus become a therapeutic approach more commonly used in
Europe where it accounted for 25% of all indications for liver transplantation. Improvement
of survival of cirrhotic patients given by the pharmacological control of HBV and HCV, has
led to an increased rate of survival and lower rate of recurrent HCC. In fact, HCC has gradually
become the most common complication in cirrhotic patients. In the last three years the number
of patients with HCC in transplant list has grown dramatically: more than 30% in France, 26%
in Europe, 34% in the United States [92, 93].
7. The role of liver transplant from living donor
Living donor liver transplantation (LDLT) is a practice used mainly in Asia, where orthotopic
organs are not readily available. Its use was later extended to other countries, mostly in Europe
and North America to compensate for the shortage of organs and the long time on the waiting
list which leads to patients’ death, or dropout for medical reasons or progression of cancer
beyond acceptable transplant criteria.
The main requirement of the transplant from a living donor is the "donor safety", namely
the protection of the donor. Although the risks of this intervention in specialized centers are
very low, the incidence of death of the donor ranges from 0.15 to 0.30%, but can reach up to
0.50%. The concept of "double equipoise" was proposed to describe the balance that must be
maintained between the  benefits  related to  the  survival  of  the  recipient  and the  risk  of
morbidity/mortality  of  the  healthy  donor.  For  example,  in  Europe  and  North  America
transplantation for acute liver failure from a living donor is not accepted, as the mortality of
the recipient in such cases is higher. Some studies have suggested a higher risk of tumor
recurrence related to liver regeneration after transplantation using a hemiliver from living
donor compared to cadaveric whole liver. Other studies have shown no significant differen‐
ces related to the type of graft used, and the only risk factor appeared to be related to the
timing of transplantation from a living donor (fast-tracked patients), a short interval between
the  diagnosis  of  HCC  and  transplantation  whaich  can  lead  to  a  greater  risk  of  tumor
recurrence in the short term related to the fact that the biological behavior of HCC has not
yet fully manifested. For these reasons, it is generally required to have a wiat time ofat least
three months between the diagnosis of HCC and transplant before offering a graft from a
living  donor.  The  transplant  from a  living  donor  is  acceptable  if  the  5-year  survival  is
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comparable to that of patients transplanted from cadaveric donor. The use of cadaveric donors
in the event of failure of the graft is generally accepted. The need for re-transplantation is
still very low however, and the survival after re-OLT is high. In patients transplanted for
HCC from a living donor within regionally accepted criteria,  re-transplantation for graft
failure using a cadaveric liver is also possible and accepted by the scientific community. If
the transplant from a living donor had been done over the criteria,  re-transplant from a
cadaver is not recommended [94–98].
8. Inclusion criteria
Currently, in many countries, the eligibility criteria for transplantation for HCC follow "Milan
criteria" [9]:
• the presence of a single tumor of less than or equal to 5 cm in size;
• up to three tumors of size less than or equal to 3 cm;
• absence of extrahepatic or lymph node metastases;
• absence of tumor thrombosis of the portal veins, or hepatic veins per liver imaging.
The tumor should be considered unresectablebased on the location, major vessel involvement,
or if the tumor is multifocal or the patient has advanced cirrhosis (Child class B or C) [9, 99].
The expansion of the Milan criteria with the criteria of San Francisco (1 nodule < 6.5 cm in
diameter or multiple nodules of 4.5 cm in diameter with the sum of the diameters < 8cm)
had mixed results in terms of survival (survival at 5 years of 50%); for patients with HCC
outside  the  limits  of  the  criteria  of  Milan,  the  survival  tends  to  decrease  mainly  in  the
recurrence of disease. Survival that is reduced to less than 50% at five years after transplan‐
tation is considered not acceptable. Given the scarcity of available organs, many countries
circumscribe selection of patients exclusively to the Milan criteria. In practice, the problem
of the shortage of organs is the principal factor influencing the indications for transplanta‐
tion. Therefore, it became mandatory to tranplant only patients who can reach an adequate
survival.
The "United Network of Organ Sharing or UNOS" has rejected the use of CTP classification to
prioritize HCC patients on the waiting list, who may have an increased risk of mortality while
on the waiting list. The MELD system became the standard method for assessing the clinical
severity of a patient potentially candidate for liver transplantation. It is based on a numerical
score that takes into account the levels of serum creatinine, total bilirubin and INR. The score
is calculated according to the formula:
9.57*log (creatinin mg/dl) + 11.2*log (INR) +3.78*log (Bilirubin mg/dl) + 6.43
This formula calculates the risk of 3-months mortality. Patients with high scores have priority
on the waiting list for transplantation [100].
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The limit above which a patient can be enrolled into a waiting list is of MELD 15; whenever
the MELD is less than 15 the risk of the transplantation is certainly greater than the risk of
mortality by three months in the absence of transplantation. Since patients with HCC often
have a MELD < 15 and therefore a lower priority of transplantation, UNOS considered to assign
all patients with HCC (T1-T2) a MELD of 22, regardless of the actual state of liver disease. This,
however, several others factors are still considered.
In addition to the number and size of lesions (Milan criteria) and serum creatinine, bilirubin
and INR (MELD score), great importance is also given to the values of the α-FP. Although
there is not a cut-off default, in patients with cirrhosis and HCC, if α-FP levels is increasing by
more than 15 microg / L per month, liver transplantation is associated with a 5-year survival
of less than 54%. Consequently, α-FP is considered a marker of related HCC aggressiveness
and therefore should be considered to select potential candidates [101].
9. Prognosis
The main causes of death after liver transplantation are:
• Perioperative generalized morbidity causes such as multi-organ failure, cerebrovascular,
cardiovascular, pulmonary and renal complications (29%).
• Recurrence of the primary disease (20%), especially tumors (11%).
• Sepsis (18%), especially bacterial (9%).
• Technical complications (5%), especially bleeding and vascular disorders (3%).
• Rejection (4%), especially chronic (3%).
Intraoperative death and liver failure represent 3% of all deaths.
Over the past 10 years there is a decrease in mortality in the range of 16%.
Survival after transplantation account for 82% at 1 year, 71% at 5 years, 61% at 10 years, 51%
at 15 years and 43% at 20 years.
Survival has improved over the time reaching 85% at one year in 2004, compared to 76% in
1990-1994 to only 33% in 1985 (please list reference(s)..). This improvement over the time is
most evident in liver transplantation for liver tumor.
From 1988 to 2009, 5-year survival was statistically higher for patients with cirrhosis (72%)
than in patients with primary liver cancer (52%). During the last 10 years, post transplant
survival for cirrhosis and liver cancer tended to approach (73 vs. 64%).
Moreover, a recent multicenter study from Europe showed that cumulative 1 and 5 year
survival for patients transplanted for HCC on cirrhosis is 86% and 70% respectively in patients
within the Milan criteria. Patients beyond the Milan criteriahad an average overall 5-year
survival of 61.5% (correct?) [92, 102].
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Etiology of liver disease
and (n. TX)
Years (1999-2009)
1 year actuarial survival (%) 5 years actuarial survival (%)
Graft (%) Pazient (%) Graft (%) Pazient (%)
Acute hepatic failure
(3449) 70 76 62 69
Colostatic disease (4675) 83 89 74 81
Congenital biliary
pathology (2167) 84 90 79 87
Cirrhosis (25424) 81 85 69 73
Primary liver tumors
(7640) 81 83 61 64
Metastatic tumors (361) 77 83 50 55
Metabolic diseases
(2866) 82 87 72 79
Budd Chiari (400) 76 81 66 73
Table 4. Patients and graft survival over the last 10 years (adat from European studies of liver transplant for HCC
(correct?). Modified from [92]
10. Follow-up and treatment of recurrence
The main concern for patients subjected to liver transplant for HCC is recurrence that occurs
in 8 to 20% (reference). Recurrence usually occurs within the first two years and is associated
with a median survival of less than one year from the time of diagnosis (range 7-18 months).
The adoption of α-FP assay and imaging (ultrasound, CT and MRI) every six months in the
course of the follow-up has resulted in early detection of recurrence, allowing for a possible
treatment to more than 1/3 of the cases.
Recent studies have tried to identify the role of post-transplant adjuvant therapy, but results,
while highlighting a benefit in terms of overall survival and disease-free interval, are not
conclusive because of their variability in terms of chemotherapeutic regimen, dosage, inclusion
criteria and end points.
Sorafenib is a tyrosine kinase multi-targeted inhibitor, approved for treatment of patients with
advanced HCC. However, its use post-transplant is not permitted outside of clinical trials.
Loco-regional therapies for HCC recurrence (RF, TACE) and resection have been used in
patients with limited burden of disease and appear to be useful in selected cases. In conclusion,
the HCC recurrence after transplantation provides surgery for resectable lesions or through
loco-regional therapies or systemic therapies (including Sorafenib) for unresectable lesions.
Liver re-transplantation for HCC recurrence is not established [103–106].
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11. Summary
Surgical treatment of HCC has evolved over the last 20 years due to improvements in surgical
technique, anesthesiologist care and in particular to more appropriate criteria for carrying out
resection or liver transplantation. Using systematic screening of at-risk groups has increased
the detection of HCC at an early stage, potentially curable.
Survival rates following HCC surgical treatments, which were disappointing in the past, are
very high today exceeding 50% at 5 years, both with resection as well as with transplantation
in the category of single and small HCC. The choice between transplant and resection is
eventually related to liver function that may be compromised by coexisting cirrhosis, and the
availability of grafts that is currently lacking.
The biggest flaw of hepatic resection remains its high rate of relapse of the disease. In part, due
to true recurrence, and partly due to the emergence of new HCC. In this situation it is possible
to consider a transplant rescue, a second resection or local therapy options if the disease is
limited to the liver, or systemic therapies if metastatic.
A most relevant concern remains that of high risk HCC for which transplantation is precluded.
In this category of HCC resection with very strict indications can still meet a decent expectation
of survival.
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